NEW YORK, July 21, 2017 /PRNewswire/ --
If you want a Stock Review on AMDA, NVCN, ARAY, or NUVA then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com is currently scanning these four equities: Amedica Corp. (NASDAQ: AMDA), Neovasc Inc. (NASDAQ: NVCN), Accuray Inc. (NASDAQ: ARAY), and
Salt Lake City, Utah headquartered Amedica Corp.'s stock finished Thursday's session 5.52% higher at $0.40. A total volume of 536,662 shares was traded, which was above their three months average volume of 485,310 shares. Over the last month and the previous three months, the Company's shares have advanced 31.46% and 6.95%, respectively. The stock is trading above its 50-day moving average by 13.69%. Moreover, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have a Relative Strength Index (RSI) of 56.98. Your complete research report on AMDA can be retrieved for free at:
Shares in Richmond, Canada headquartered Neovasc Inc. rose 0.79%, ending yesterday's session at $1.27 with a total trading volume of 74,214 shares. The stock is trading 5.12% below its 200-day moving average. Shares of the Company, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 33.30. A free report on NVCN is just a click away at:
On Thursday, Sunnyvale, California headquartered Accuray Inc.'s stock finished flat at $4.60. A total volume of 605,801 shares was traded. The Company's shares have advanced 3.37% in the last one month. The stock is trading 5.83% above its 50-day moving average. Additionally, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 54.57.
On July 11th, 2017, Accuray announced that it is expanding access to its products in the Middle-East with the signing of an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates, for the acquisition of one CyberKnife® M6™ System and one Radixact™ System. The deal was entered into backlog during the Company's fourth fiscal quarter, which ended on June 30th, 2017. Sign up for your complimentary research report on ARAY at:
Shares in San Diego, California headquartered NuVasive Inc. ended the day 0.75% higher at $81.11 with a total trading volume of 519,414 shares. The stock has gained 4.59% in the last one month, 7.15% in the previous three months, and 20.41% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 6.71% and 14.27%, respectively. Furthermore, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 67.77.
On July 05th, 2017, NuVasive announced that it will release its Q2 2017 earnings results on July 27, 2017, after the close of the market. The Company will hold a conference call on the same day at 4:30 p.m. ET to discuss the results of its Q2 2017 financial performance. A live webcast of the conference call will be available under the Investor Relations page of the Company's website. Register for free on DailyStockTracker.com and download the latest research report on NUVA at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...View All